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CVac is an autologous cellular therapy targeted to elicit a
T cell response to tumors that over-express mucin
1. CAN-003 is a randomized, open-label, Phase 2 trial
evaluating the safety and efficacy of CVac given as a single
agent to epithelial ovarian cancer (EOC) patients who are
in complete remission (CR) following first or second-line
chemotherapy. Patients were eligible if they had stage III
or IV EOC and obtained a complete response to standard
first or second line platinum/ taxane based chemotherapy.
The first 7 patients received CVac to allow evaluation of
manufacturing in the US and for safety evaluation. Patients
were randomized to CVac therapy or standard of care
(SOC). Patients in the active group were treated with up
to 10 doses of CVac, 4 weekly for 7 doses, and 8 weekly
for 3 doses. The trial is closed to enrolment and completes
in 2013. 63 patients were enrolled into the trial; 42 were in
1st remission (age 55.7+/- 9.2 y) and 21 were in 2nd
remission (age 56.8+/-9.0 y). 60 were Caucasian, 1 African
American and 2 Asian. 36 treated patients and 27 OSC
(data until Dec 12 2013). 10 SAEs were reported in total.
7 SAEs in CVac patients and 3 SAEs were reported in
SOC; none were unexpected and only one (abdominal
pain) was classified as possibly-related to CVac. Interim
analysis has shown positive trends in PFS; as of 17 August
2012, the median PFS for days on study as 365 d for CVac,
421 d for non-randomized CVac, and 321 d for OSC.
Updated PFS data will be presented at the meeting. Over-
all survival data is being collected and will be presented at
the meeting. As expected, assessment of anti-mucin-1
responses have indicated no humoral response, however,
interim immune monitoring results show a T cell response
that is mucin 1-specific after 3 CVac doses. No mucin 1
response was observed in normal healthy volunteers nor
untreated patients. The complete T-cell responses analysis
throughout the course of CVac treatment will be pre-
sented at the meeting. In conclusion, study data show that
immunotherapy with CVac is well tolerated. Immunologi-
cal outcomes are consistent with the mechanism of action
and the interim trends are encouraging for PFS.
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